News / Korea / yonhap_finance
Alteogen Shares Rise on 520 Billion Won Licensing Deal
Health Technology · Biotechnology · yonhap_finance · 2026-08-05
196170
Alteogen shares climbed over 4% in early trading following the announcement of a licensing agreement worth up to 520 billion won with a global pharmaceutical firm.
What Happened
Licensing Deal: Alteogen announced a licensing agreement with a global pharmaceutical company valued at up to $365 million (approximately 521.9 billion won).
Technology Details: The deal involves the use of Alteogen's proprietary 'ALT-B4' hyaluronidase technology to develop and commercialize subcutaneous (SC) formulations of biological drugs.
Market Reaction: Reflecting optimism over the technology export, Alteogen's stock price rose 4.12% to 278,000 won in early trading.
Strategic Importance: Under the agreement, the partner gains exclusive rights to develop and commercialize products utilizing the ALT-B4 platform, marking a significant milestone for Alteogen.